Wells Fargo Adds ViroPharma (VPHM) to Its Priority List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Viropharma, Inc. (VPHM) Tops Q4 EPS by 7c; Guides FY Sales In-Line
February 27, 2013 7:33 AM ESTViropharma, Inc. (NASDAQ: VPHM) reported Q4 EPS of $0.10, $0.07 better than the analyst estimate of $0.03. Revenue for the quarter came in at $106.5 million versus the consensus estimate of $103.06 million.
Viropharma, Inc. sees FY2013 revenue of $450-475 million, versus the consensus of $460.07 million.
For... More
